Cerebrovascular Reactivity Impairment in Preclinical Alzheimer's Disease
ABSTRACT BACKGROUND AND PURPOSE A substantial overlap exists between declines in cerebral vasoreactivity (CVR) and symptomatic Alzheimer's disease (AD). CVR can be quantified using transcranial Doppler (TCD) measurement of cerebral blood flow velocities (CBFV) in the middle cerebral artery (MCA...
Gespeichert in:
| Veröffentlicht in: | Journal of neuroimaging 2019-07, Vol.29 (4), p.493-498 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 498 |
|---|---|
| container_issue | 4 |
| container_start_page | 493 |
| container_title | Journal of neuroimaging |
| container_volume | 29 |
| creator | Alwatban, Mohammed Murman, Daniel L. Bashford, Greg |
| description | ABSTRACT
BACKGROUND AND PURPOSE
A substantial overlap exists between declines in cerebral vasoreactivity (CVR) and symptomatic Alzheimer's disease (AD). CVR can be quantified using transcranial Doppler (TCD) measurement of cerebral blood flow velocities (CBFV) in the middle cerebral artery (MCA) with CO2 as a vasodilatory stimulus. The breath‐hold acceleration index (BHAI) is a new, more reliable measure of CVR developed recently in our laboratory. Our primary goal is to explore the possibility of using TCD for asymptomatic AD screening.
METHODS
A pilot study population was divided into three groups: 9 healthy control subjects, 8 subjects identified as preclinical AD, and 10 patients diagnosed with prodromal or mild AD. Control subjects had a Clinical Dementia Rating (CDR) score of 0 without elevated amyloid‐β (Aβ) on amyloid positron emission tomography (PET) imaging, preclinical AD subjects had CDR = 0 with elevated Aβ, and prodromal to mild AD subjects had CDR scores ≥.5 and elevated Aβ. CVR was calculated using two indices: the conventional breath‐holding index (BHI) and the new BHAI. TCD parameters between the three groups were compared.
RESULTS
BHAI was able to distinguish between 9 normal control subjects and 8 preclinical‐AD subjects with high statistical significance (P |
| doi_str_mv | 10.1111/jon.12606 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2229096881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2251600014</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4196-efb6c5e054856c2b2c391afc278e15087258c362e7113116436a71b8eb72c8093</originalsourceid><addsrcrecordid>eNp10D1PwzAQBmALgWgpDPwBFIkBGEJ9Tuw4Y1U-WlRRhGCOHHMVrvJR7KSo_HoMKQxIeDkPz706vYQcA70E_4bLuroEJqjYIX3gnIWCi3TX_ymHkDEZ98iBc0tKGcQs2ie9iCaxpDzqk8kYLea2Xiun20LZ4BGVbszaNJtgWq6UsSVWTWCq4MGiLkxltCqCUfHxiqZEe-aCK-NQOTwkewtVODzazgF5vrl-Gk_C2fx2Oh7NQh1DKkJc5EJzpDyWXGiWMx2loBaaJRKBU5kwLnUkGCYAEYCII6ESyCXmCdOSptGAnHe5K1u_teiarDROY1GoCuvWZYyxlKZCSvD09A9d1q2t_HVecRCUUoi9uuiUtrVzFhfZyppS2U0GNPuq129V2Xe93p5sE9u8xJdf-dOnB8MOvJsCN_8nZXfz-y7yEyezgeM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2251600014</pqid></control><display><type>article</type><title>Cerebrovascular Reactivity Impairment in Preclinical Alzheimer's Disease</title><source>Wiley Online Library - AutoHoldings Journals</source><creator>Alwatban, Mohammed ; Murman, Daniel L. ; Bashford, Greg</creator><creatorcontrib>Alwatban, Mohammed ; Murman, Daniel L. ; Bashford, Greg</creatorcontrib><description>ABSTRACT
BACKGROUND AND PURPOSE
A substantial overlap exists between declines in cerebral vasoreactivity (CVR) and symptomatic Alzheimer's disease (AD). CVR can be quantified using transcranial Doppler (TCD) measurement of cerebral blood flow velocities (CBFV) in the middle cerebral artery (MCA) with CO2 as a vasodilatory stimulus. The breath‐hold acceleration index (BHAI) is a new, more reliable measure of CVR developed recently in our laboratory. Our primary goal is to explore the possibility of using TCD for asymptomatic AD screening.
METHODS
A pilot study population was divided into three groups: 9 healthy control subjects, 8 subjects identified as preclinical AD, and 10 patients diagnosed with prodromal or mild AD. Control subjects had a Clinical Dementia Rating (CDR) score of 0 without elevated amyloid‐β (Aβ) on amyloid positron emission tomography (PET) imaging, preclinical AD subjects had CDR = 0 with elevated Aβ, and prodromal to mild AD subjects had CDR scores ≥.5 and elevated Aβ. CVR was calculated using two indices: the conventional breath‐holding index (BHI) and the new BHAI. TCD parameters between the three groups were compared.
RESULTS
BHAI was able to distinguish between 9 normal control subjects and 8 preclinical‐AD subjects with high statistical significance (P < .001). BHI and pulsatility index were able only to distinguish AD from healthy and preclinical subjects (P < .001).
CONCLUSIONS
In this exploratory pilot study, CVR was significantly decreased in preclinical, prodromal, and mild AD subjects as compared to the healthy group. Lower CVR in the preclinical AD group was detected using the new BHAI index but not the conventional BHI index.</description><identifier>ISSN: 1051-2284</identifier><identifier>EISSN: 1552-6569</identifier><identifier>DOI: 10.1111/jon.12606</identifier><identifier>PMID: 30748053</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acceleration ; Alzheimer's disease ; Amyloid ; Blood flow ; breath‐holding index ; Carbon dioxide ; Cerebral blood flow ; cerebrovascular reactivity ; Dementia disorders ; Neurodegenerative diseases ; Neuroimaging ; Population (statistical) ; Population studies ; Positron emission ; Positron emission tomography ; preclinical Alzheimer's diseases ; Tomography ; transcranial Doppler ultrasound ; Ultrasound</subject><ispartof>Journal of neuroimaging, 2019-07, Vol.29 (4), p.493-498</ispartof><rights>2019 by the American Society of Neuroimaging</rights><rights>2019 by the American Society of Neuroimaging.</rights><rights>2019 American Society of Neuroimaging</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4196-efb6c5e054856c2b2c391afc278e15087258c362e7113116436a71b8eb72c8093</citedby><cites>FETCH-LOGICAL-c4196-efb6c5e054856c2b2c391afc278e15087258c362e7113116436a71b8eb72c8093</cites><orcidid>0000-0003-0184-1533</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjon.12606$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjon.12606$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30748053$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alwatban, Mohammed</creatorcontrib><creatorcontrib>Murman, Daniel L.</creatorcontrib><creatorcontrib>Bashford, Greg</creatorcontrib><title>Cerebrovascular Reactivity Impairment in Preclinical Alzheimer's Disease</title><title>Journal of neuroimaging</title><addtitle>J Neuroimaging</addtitle><description>ABSTRACT
BACKGROUND AND PURPOSE
A substantial overlap exists between declines in cerebral vasoreactivity (CVR) and symptomatic Alzheimer's disease (AD). CVR can be quantified using transcranial Doppler (TCD) measurement of cerebral blood flow velocities (CBFV) in the middle cerebral artery (MCA) with CO2 as a vasodilatory stimulus. The breath‐hold acceleration index (BHAI) is a new, more reliable measure of CVR developed recently in our laboratory. Our primary goal is to explore the possibility of using TCD for asymptomatic AD screening.
METHODS
A pilot study population was divided into three groups: 9 healthy control subjects, 8 subjects identified as preclinical AD, and 10 patients diagnosed with prodromal or mild AD. Control subjects had a Clinical Dementia Rating (CDR) score of 0 without elevated amyloid‐β (Aβ) on amyloid positron emission tomography (PET) imaging, preclinical AD subjects had CDR = 0 with elevated Aβ, and prodromal to mild AD subjects had CDR scores ≥.5 and elevated Aβ. CVR was calculated using two indices: the conventional breath‐holding index (BHI) and the new BHAI. TCD parameters between the three groups were compared.
RESULTS
BHAI was able to distinguish between 9 normal control subjects and 8 preclinical‐AD subjects with high statistical significance (P < .001). BHI and pulsatility index were able only to distinguish AD from healthy and preclinical subjects (P < .001).
CONCLUSIONS
In this exploratory pilot study, CVR was significantly decreased in preclinical, prodromal, and mild AD subjects as compared to the healthy group. Lower CVR in the preclinical AD group was detected using the new BHAI index but not the conventional BHI index.</description><subject>Acceleration</subject><subject>Alzheimer's disease</subject><subject>Amyloid</subject><subject>Blood flow</subject><subject>breath‐holding index</subject><subject>Carbon dioxide</subject><subject>Cerebral blood flow</subject><subject>cerebrovascular reactivity</subject><subject>Dementia disorders</subject><subject>Neurodegenerative diseases</subject><subject>Neuroimaging</subject><subject>Population (statistical)</subject><subject>Population studies</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>preclinical Alzheimer's diseases</subject><subject>Tomography</subject><subject>transcranial Doppler ultrasound</subject><subject>Ultrasound</subject><issn>1051-2284</issn><issn>1552-6569</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp10D1PwzAQBmALgWgpDPwBFIkBGEJ9Tuw4Y1U-WlRRhGCOHHMVrvJR7KSo_HoMKQxIeDkPz706vYQcA70E_4bLuroEJqjYIX3gnIWCi3TX_ymHkDEZ98iBc0tKGcQs2ie9iCaxpDzqk8kYLea2Xiun20LZ4BGVbszaNJtgWq6UsSVWTWCq4MGiLkxltCqCUfHxiqZEe-aCK-NQOTwkewtVODzazgF5vrl-Gk_C2fx2Oh7NQh1DKkJc5EJzpDyWXGiWMx2loBaaJRKBU5kwLnUkGCYAEYCII6ESyCXmCdOSptGAnHe5K1u_teiarDROY1GoCuvWZYyxlKZCSvD09A9d1q2t_HVecRCUUoi9uuiUtrVzFhfZyppS2U0GNPuq129V2Xe93p5sE9u8xJdf-dOnB8MOvJsCN_8nZXfz-y7yEyezgeM</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Alwatban, Mohammed</creator><creator>Murman, Daniel L.</creator><creator>Bashford, Greg</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0184-1533</orcidid></search><sort><creationdate>201907</creationdate><title>Cerebrovascular Reactivity Impairment in Preclinical Alzheimer's Disease</title><author>Alwatban, Mohammed ; Murman, Daniel L. ; Bashford, Greg</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4196-efb6c5e054856c2b2c391afc278e15087258c362e7113116436a71b8eb72c8093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acceleration</topic><topic>Alzheimer's disease</topic><topic>Amyloid</topic><topic>Blood flow</topic><topic>breath‐holding index</topic><topic>Carbon dioxide</topic><topic>Cerebral blood flow</topic><topic>cerebrovascular reactivity</topic><topic>Dementia disorders</topic><topic>Neurodegenerative diseases</topic><topic>Neuroimaging</topic><topic>Population (statistical)</topic><topic>Population studies</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>preclinical Alzheimer's diseases</topic><topic>Tomography</topic><topic>transcranial Doppler ultrasound</topic><topic>Ultrasound</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alwatban, Mohammed</creatorcontrib><creatorcontrib>Murman, Daniel L.</creatorcontrib><creatorcontrib>Bashford, Greg</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuroimaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alwatban, Mohammed</au><au>Murman, Daniel L.</au><au>Bashford, Greg</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cerebrovascular Reactivity Impairment in Preclinical Alzheimer's Disease</atitle><jtitle>Journal of neuroimaging</jtitle><addtitle>J Neuroimaging</addtitle><date>2019-07</date><risdate>2019</risdate><volume>29</volume><issue>4</issue><spage>493</spage><epage>498</epage><pages>493-498</pages><issn>1051-2284</issn><eissn>1552-6569</eissn><abstract>ABSTRACT
BACKGROUND AND PURPOSE
A substantial overlap exists between declines in cerebral vasoreactivity (CVR) and symptomatic Alzheimer's disease (AD). CVR can be quantified using transcranial Doppler (TCD) measurement of cerebral blood flow velocities (CBFV) in the middle cerebral artery (MCA) with CO2 as a vasodilatory stimulus. The breath‐hold acceleration index (BHAI) is a new, more reliable measure of CVR developed recently in our laboratory. Our primary goal is to explore the possibility of using TCD for asymptomatic AD screening.
METHODS
A pilot study population was divided into three groups: 9 healthy control subjects, 8 subjects identified as preclinical AD, and 10 patients diagnosed with prodromal or mild AD. Control subjects had a Clinical Dementia Rating (CDR) score of 0 without elevated amyloid‐β (Aβ) on amyloid positron emission tomography (PET) imaging, preclinical AD subjects had CDR = 0 with elevated Aβ, and prodromal to mild AD subjects had CDR scores ≥.5 and elevated Aβ. CVR was calculated using two indices: the conventional breath‐holding index (BHI) and the new BHAI. TCD parameters between the three groups were compared.
RESULTS
BHAI was able to distinguish between 9 normal control subjects and 8 preclinical‐AD subjects with high statistical significance (P < .001). BHI and pulsatility index were able only to distinguish AD from healthy and preclinical subjects (P < .001).
CONCLUSIONS
In this exploratory pilot study, CVR was significantly decreased in preclinical, prodromal, and mild AD subjects as compared to the healthy group. Lower CVR in the preclinical AD group was detected using the new BHAI index but not the conventional BHI index.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30748053</pmid><doi>10.1111/jon.12606</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-0184-1533</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1051-2284 |
| ispartof | Journal of neuroimaging, 2019-07, Vol.29 (4), p.493-498 |
| issn | 1051-2284 1552-6569 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2229096881 |
| source | Wiley Online Library - AutoHoldings Journals |
| subjects | Acceleration Alzheimer's disease Amyloid Blood flow breath‐holding index Carbon dioxide Cerebral blood flow cerebrovascular reactivity Dementia disorders Neurodegenerative diseases Neuroimaging Population (statistical) Population studies Positron emission Positron emission tomography preclinical Alzheimer's diseases Tomography transcranial Doppler ultrasound Ultrasound |
| title | Cerebrovascular Reactivity Impairment in Preclinical Alzheimer's Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T04%3A56%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cerebrovascular%20Reactivity%20Impairment%20in%20Preclinical%20Alzheimer's%20Disease&rft.jtitle=Journal%20of%20neuroimaging&rft.au=Alwatban,%20Mohammed&rft.date=2019-07&rft.volume=29&rft.issue=4&rft.spage=493&rft.epage=498&rft.pages=493-498&rft.issn=1051-2284&rft.eissn=1552-6569&rft_id=info:doi/10.1111/jon.12606&rft_dat=%3Cproquest_cross%3E2251600014%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2251600014&rft_id=info:pmid/30748053&rfr_iscdi=true |